Reasons for breast cancer heterogeneity

por Bertucci, François, Birnbaum, Daniel
Publicado 2008

Distant metastasis: not out of reach any more

por Bertucci, François, Birnbaum, Daniel
Publicado 2009

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

por Bertucci, Alexandre, Bertucci, François, Gonçalves, Anthony
Publicado 2023

Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features

por Bertucci, François, Chetaille, Bruno, Xerri, Luc
Publicado 2011

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy

por Bertucci, François, Finetti, Pascal, Birnbaum, Daniel
Publicado 2015

XPO1, therapeutic … and prognostic target in sarcomas

por Bertucci, François, Finetti, Pascal, Birnbaum, Daniel
Publicado 2016

Bevacizumab in HER2-negative inflammatory breast cancer

por Bertucci, François, Goncalves, Anthony, Viens, Patrice
Publicado 2016

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

por Gonçalves, Anthony, Bertucci, Alexandre, Bertucci, François
Publicado 2020

Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations

por Bertucci, François, Van Laere, Steven, Birnbaum, Daniel
Publicado 2020

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

por Nicolas, Emanuel, Bertucci, François, Sabatier, Renaud, Gonçalves, Anthony
Publicado 2018

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype

por Bertucci, François, Finetti, Pascal, Goncalves, Anthony, Birnbaum, Daniel
Publicado 2020

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

por Goncalves, Anthony, Finetti, Pascal, Birnbaum, Daniel, Bertucci, François
Publicado 2021

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer

por Bertucci, François, De Nonneville, Alexandre, Finetti, Pascal, Mamessier, Emilie
Publicado 2023

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps

por Bertucci, François, Finetti, Pascal, Mamessier, Emilie, De Nonneville, Alexandre
Publicado 2023

Sacituzumab govitecan in triple-negative breast cancer

por de Nonneville, Alexandre, Goncalves, Anthony, Mamessier, Emilie, Bertucci, François
Publicado 2022

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity

por Mamessier, Emilie, Bertucci, François, Sabatier, Renaud, Birnbaum, Daniel, Olive, Daniel
Publicado 2012

Dramatic and Delayed Response to Doxorubicin-Dacarbazine Chemotherapy of a Giant Desmoid Tumor: Case Report and Literature Review

por Monneur, Audrey, Chetaille, Bruno, Perrot, Delphine, Guiramand, Jérôme, Bertucci, François
Publicado 2013

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy

por de Nonneville, Alexandre, Boudin, Laurys, Houvenaeghel, Gilles, Gonçalves, Anthony, Bertucci, François
Publicado 2023

Validation and comparison of the molecular classifications of pancreatic carcinomas

por Birnbaum, David J., Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie, Bertucci, François
Publicado 2017

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors

por Birnbaum, David Jérémie, Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie
Publicado 2019